ANDA 208150, held by Apotex. Fluticasone Propionate.
As of Nov 16, 2026, ANDA 208150 (Fluticasone Propionate), held by Apotex, was first approved by FDA on Feb 29, 2016, with 1 approved supplement and 0 published complete response letters.
Use s Temporarily relieves these symptoms of hay fever or other upper respiratory allergies:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 29, 2016 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fluticasone Propionate0.05MG/SPRAY · spray, metered;nasal | Fluticasone Propionate | OTC |
| Oct 20, 2017 | Supplement 5Labeling · Standard review | Approved | None posted |
| Feb 29, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters